Regeneron(US:REGN) Globenewswire·2025-10-31 11:00Core Insights - Dupixent (dupilumab) has been awarded the "Best Biotechnology Product" of 2025 by the Galien Foundation, recognizing its significant scientific innovation and impact on various allergic and atopic conditions [1][2] - It is the first and only therapy specifically targeting the IL-4 and IL-13 signaling pathways, which are key drivers of type 2 inflammation [1][2] Company Overview - Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on developing life-transforming medicines for serious diseases [23] - The company utilizes proprietary technologies, such as VelocImmune, to create optimized fully human antibodies [22][24] Product Details - Dupixent is approved for eight indications globally, including atopic dermatitis, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, bullous pemphigoid, prurigo nodularis, and chronic obstructive pulmonary disease (COPD) [3][6] - More than 1 million patients are currently being treated with Dupixent worldwide [2][6] Scientific Significance - Dupixent was developed based on a hypothesis that many allergic and atopic diseases are driven by excess IL-4 and IL-13, with Phase 3 trials demonstrating significant clinical benefits [2][5] - It is the first dual blocker of IL-4 and IL-13 approved by the U.S. FDA, highlighting its unique position in the market [2][5] Clinical Development - Dupixent has been studied in over 60 clinical trials involving more than 10,000 patients, focusing on chronic diseases associated with type 2 inflammation [8][9] - The product is jointly developed by Regeneron and Sanofi under a global collaboration agreement [7] Future Prospects - Regeneron and Sanofi are exploring additional indications for Dupixent in Phase 3 trials, including chronic pruritus of unknown origin and lichen simplex chronicus [9]